Suzuki K, Obata K, Fukatsu H, Ohgushi N, Okishio N, Tochigi H, Sakai S, Shinoda M, Ushiyama T, Takashi M
Nihon Hinyokika Gakkai Zasshi. 1990 Jan;81(1):96-102. doi: 10.5980/jpnjurol1989.81.96.
During the 7 years from 1980 to 1986, 2860 cases of bladder tumors were registered in the Tokai Urological Cancer Registry. Among the 2860 cases, 2304 cases were selected from the registered cases for the present study. The 5-year relative (actual) survival rates were 73.8% (61.9%) of all patients; 48.9% (42.4%) in those with malignant neoplasma of urinary bladder excluding transitional cell carcinoma; 48.8% (41/3%) in those with mixed tumor. In patients with transitional cell carcinoma, the 5-year relative (actual survival rates were 93.7% (78.8%) for G1, 87.2% (74.1%) for G2 and 47.3% (38.9%) for G3. As to staging, the 5-year survival rates were 101.9% (88.0%), 87.6% (75.3%), 57.9% (47.8%), 33.7% (28.2%) and 6.1% (5.0%) in patients with stage of Ta, T1, T2, T3 and T4, respectively. The tumors with muscle infiltration and high grade malignancy obviously deteriorated patients' survival. The 5-year relative (actual) survival rate for patients treated with TUR was 98.1% (82.2%). As to grading, the 5-year survival rates were 102.2% (86.6%) for G1, 104.3% (88.3%) for G2 and 56.9% (48.3%) for G3. The 5-year survival rates of those with Ta, T1 and T2 were 103.9% (89.7%), 96.0% (82.6) and 61.1% (49.1%), respectively. The 5-year relative (actual) survival rate for patients undergoing total cystectomy was 62.4% (52.3%). In those patients, the 5-year survival rates were 96.7% (80.9%) for G1, 63.6% (55.7%) for G2 and 55.4% (47.1%) for G3. As to staging, the 5-year survival rates were 102.3% (90.6%), 77.8% (68.2%), 56.3% (47.9%), 41.8% (34.9%) and 15.2% (13.1%) in patients with stage of Ta, T1, T2, T3 and T4, respectively. The 3 and 5-year relative (actual) survival rates in patients with advanced bladder tumors were 5.3% (4.8%) and 0.87% (0.73%), respectively.
1980年至1986年的7年间，东海泌尿生殖系统癌症登记处登记了2860例膀胱肿瘤病例。在这2860例病例中，选取了2304例登记病例用于本研究。所有患者的5年相对（实际）生存率为73.8%（61.9%）；膀胱恶性肿瘤（不包括移行细胞癌）患者的5年相对（实际）生存率为48.9%（42.4%）；混合性肿瘤患者的5年相对（实际）生存率为48.8%（41.3%）。在移行细胞癌患者中，G1级的5年相对（实际）生存率为93.7%（78.8%），G2级为87.2%（74.1%），G3级为47.3%（38.9%）。就分期而言，Ta期、T1期、T2期、T3期和T4期患者的5年生存率分别为101.9%（88.0%）、87.6%（75.3%）、57.9%（47.8%）、33.7%（28.2%）和6.1%（5.0%）。伴有肌肉浸润和高级别恶性肿瘤的肿瘤明显降低了患者的生存率。接受经尿道膀胱肿瘤切除术（TUR）治疗的患者的5年相对（实际）生存率为98.1%（82.2%）。就分级而言，G1级的5年生存率为102.2%（86.6%），G2级为104.3%（88.3%），G3级为56.9%（48.3%）。Ta期、T1期和T2期患者的5年生存率分别为103.9%（89.7%）、96.0%（82.6%）和61.1%（49.1%）。接受全膀胱切除术的患者的5年相对（实际）生存率为62.4%（52.3%）。在这些患者中，G1级的5年生存率为96.7%（80.9%），G2级为63.6%（55.7%），G3级为55.4%（47.1%）。就分期而言，Ta期、T1期、T2期、T3期和T4期患者的5年生存率分别为102.3%（90.6%）、77.8%（68.2%）、56.3%（47.9%）、41.8%（34.9%）和15.2%（13.1%）。晚期膀胱肿瘤患者的3年和5年相对（实际）生存率分别为5.3%（4.8%）和0.87%（0.73%）。
